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BRAF (alternately referred to as v-raf murine sarcoma viral oncogene homolog B1) is
a proto-oncogene involved in the mitogen-activated protein kinase (MAPK) pathway.
BRAF alterations are most commonly missense mutations or aberrant fusions. These
mutations are observed in numerous primary central nervous system tumors as well
as metastases. This review discusses the prevalence of BRAF alteration within select
notable CNS tumors, and their prognostic associations. Included are some novel entities
such as diffuse leptomeningeal glioneuronal tumor (DLGNT), polymorphous low grade
neuroepithelial tumor of the young (PLNTY), and multinodular and vacuolating neuronal
tumor (MVNT). Knowledge of this gene’s integrity in CNS and PNS tumors can have
profound diagnostic and therapeutic implications. Also reviewed are the current state of
targeted therapy against aberrant BRAF as it pertains mostly to the CNS and to a lesser
extent in PNS, and certain diagnostic aspects.
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INTRODUCTION
Personalized medicine has revolutionized cancer care in the 21st century, particularly in the areas of
diagnosis and treatment. The application of this knowledge to CNS cancer has been variable. While
the incorporation of molecular findings has become routine in diagnosing CNS tumors, particularly
with the revised 2016 WHO guidelines, targeted therapies have not become similarly common.
Patients with gliomas and other primary CNS tumors have a pressing need for new therapies. Five-
year survival for primary central nervous system tumors is an estimated 59–64% (1).
In this review, we focus on the proto-oncogene BRAF and its relevance in these aspects of
CNS and PNS tumors. We detail its normal and pathologic function, its prevalence and prognostic
relevance in select primary and metastatic neoplasms, and finally challenges and future directions
of targeted therapy.
BRAF Function
BRAF, alternately referred to as v-Raf murine sarcoma viral oncogene homolog B1, encodes for one
of three members of the rapidly accelerating fibrosarcoma (RAF) serine/threonine kinase family.
It is located on the long arm of chromosome 7 at position 34. It normally functions as part of
the mitogen activated protein kinase (MAPK) pathway, enabling cells to respond to extracellular
growth signals. Classically, these growth signals are recognized by tyrosine kinase receptors residing
within the plasma membrane, leading to a cascade of phosphorylation events involving protein
kinases of the Ras, Raf, MEK, and MAPK/ERK families. MAP kinases, in turn, activate various
signals promoting cell growth and survival (Figure 1).
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FIGURE 1 | Major oncogenic pathways MAPK and mTOR pathways. Green
font shows major genetic alteration. Red font shows proposed molecular
therapy.
Owing to this role, the MAPK pathway is frequently
implicated in human cancer. Derangement can occur by
activating events in its upstream signals, or by loss of function in
regulatory proteins, such as neurofibromin-1. Gain-of-function
mutations in BRAF commonly result from pathologic fusion or
missense mutations, these occurring in near mutually exclusive
fashion (2). In addition to its promotion of cell growth
and survival, oncogenic BRAF is also known to induce cell
senescence (3).
Mechanisms of Pathologic Activation
Gain of function in BRAF results primarily from aberration
in the N-terminal portion of the protein, which encodes for
an auto-inhibitory domain. Without this domain the protein’s
function is uncoupled from upstream signals and remains
constitutively active. BRAF fusion proteins frequently lack this
auto-inhibitory domain entirely. Fusions typically arise from
tandem duplications (70% of cases), and less often from deletions
and insertions (<3% cases) (4, 5). In the commonest variant,
the 5′ segment of the KIAA1549 gene replaces that of BRAF (6).
Numerous KIAA1549:BRAF fusion variants have been described
involving different exons (Table 1). However, 80% of fusions
involve exons 15 or 16 of KIAA1549 with exon 9 of BRAF (6).
Single nucleotide mutations can lead to similar effects (6). The
most frequent and well-studied missense mutation substitutes
valine for glutamate at position 600 (V600E) (7). Other, less
frequent, variants include V600D, V600R, and V600K (8).
These mutations are thought to induce gain of function by
mimicking the phosphorylated state of the protein, as they
TABLE 1 | Patterns of KIAA1549:BRAF fusion (32, 103, 104).
Fusion-Involved Exons
KIAA1549: BRAF
Prevalence (%)
16:9 68%
16:11 10%
15:9 9%
18:10 3%
19:7 3%
15:11–18 3%
17:10–18 3%
appear in close proximity to regulatory phosphorylation sites at
codons 598 and 601.
We detail below how distinguishing between these two
mechanisms may impact patient care. And, although rare,
it should be noted that BRAF fusions and single nucleotide
mutation may occur concurrently, as is the case in an estimated
1–3% of low grade gliomas, 3% of PA and PXA, and 1.6% of
pilocytic astrocytomas (5, 9) (Table 2).
PRIMARY CNS TUMORS
Gliomas
Low Grade Glioma
Pilocytic astrocytoma
Pilocytic astrocytoma (PA) is the commonest primary childhood
CNS tumor, accounting for 30% of the total. These tumors are
illustrative for the role of BRAF testing. Over two thirds of these
tumors arise within the posterior fossa (10). Roughly 85% of cases
are sporadic, and 15% are associated with the inherited tumor
predisposition syndrome neurofibromatosis type 1 (NF1) (11)
(Figure 2).
Despite histologic similarity, sporadic and NF1 associated
pilocytic astrocytomas exhibit different characteristics in terms of
location and clinical course. While the vast majority of pilocytic
astrocytomas are sporadic and arise in the posterior fossa, in NF1
patients 50–76% occur in the optic pathway and are known as
optic pathway gliomas (11). NF-1 patients also frequently develop
PA in the cerebral hemispheres. In fact, just 4% of cerebellar PAs
are associated with NF1. Nevertheless, both supratentorial and
infratentorial locations of PA frequently require treatment. Optic
pathway gliomas, which may threaten vision, are most often
treated with chemotherapy, while posterior-fossa PAs, which
threaten brainstem compression or obstructive hydrocephalus,
are most often resected.
These differences are believed to result from differing
underlying oncogenic mechanisms, namely BRAF and NF1
(−/−) activation of the MAPK and PI3K/mTOR pathways.
Sporadic PAs more commonly demonstrate BRAF fusion rather
than single nucleotide mutations, as nearly 80% of cerebellar PAs
harbor fusions, which most often involve KIAA1549 (Table 1
and Figure 3). However, in fewer than 5 percent of cases the
fusion involves other genes involved in the MAPK pathway such
as FAM131B, SRGAP, QK1, RNF130, CLCN6, MKRN1, GNA11,
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TABLE 2 | The frequency BRAF aberrations in primary and metastatic tumors to
the CNS (PA, pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma; DA,
diffuse astrocytoma; GBM, glioblastoma; GG/GC, ganglioglioma/gangliocytoma;
DIA, desmoplastic infantile astrocytoma/ganglioglioma; DNET, dysembryoplastic
neuroepithelial tumor; SEGA, subependymal giant cell astrocytoma; DLGNT,
diffuse leptomeningeal glioneuronal tumor; LCH, Langerhans cell histiocytosis;
MPNST, malignant peripheral nerve sheath tumor).
Tumor type Frequency of BRAF aberration
Primary CNS tumors
Glial
PA KIAA1549:BRAF fusion: 50–85%
BRAF single nucleotide variant: 9–15%
PXA BRAF single nucleotide variant:
63–70%
PXA with anaplasia BRAF single nucleotide variant: 38%
DA KIAA1549:BRAF fusion: 8% BRAF
single nucleotide variant: up to 14%
Anaplastic astrocytoma BRAF single nucleotide variant: 15%
Oligodendroglioma BRAF single nucleotide variant: 3%
Anaplastic oligodendroglioma 0%
GBM BRAF single nucleotide variant: 9%*
Ependymoma 0%
Glioneuronal
GG/GC KIAA1549:BRAF fusion: 25% BRAF
single nucleotide variant: 13–56%
DIA/G BRAF single nucleotide variant: 11%
DNET BRAF single nucleotide variant: 51%
SEGA BRAF single nucleotide variant: 43%
DLGNT KIAA1549:BRAF fusion: 65%
Meningioma
Meningioma BRAF single nucleotide variant: 0–3%**
Embryonal and neuronal tumors
Medulloblastoma 0%
CNS primitive neuroectodermal tumor 0%
Atypical teratoid/rhabdoid tumor 0%
Central neurocytoma 0%
Other tumors
Papillary craniopharyngioma BRAF single nucleotide variant: 96%
Adamantinomatous craniopharyngioma 0%
LCH BRAF single nucleotide variant: 50%
Glomus tumor BRAF single nucleotide variant: 6%
Hemangioblastoma 0%
Pituitary adenoma 0%
Peripheral nervous tumors
MPNST BRAF single nucleotide variant: 20%
Schwannoma 0%
Neurofibroma 0%
Metastatic tumors
Melanoma BRAF single nucleotide variant:
41–60%
Papillary thyroid carcinoma BRAF single nucleotide variant: 56%
Colorectal carcinoma BRAF mutation: 10–18%
*Seen with epithelioid and giant cell morphology and in the pediatric population **
rhabdoid subtype (7, 8, 32).
FZR1, and MACF1 (2, 4, 5, 12–14). V600E is not thought to play
a major role in their pathogenesis. Its prevalence in all pediatric
PAs regardless of location is estimated to be around 6% (15).
The signature molecular aberration in NF1-associated PAs, by
contrast, is loss of neurofibromin. This product of the NF1 gene is
a negative regulator of Ras. Its loss activates both the MAPK and
PI3K/mTOR signaling pathways (11, 16).
While cases have been reported of optic gliomas bearing both
KIAA1549:BRAF and NF1 loss, these are rare (17). Therefore,
these markers define two seemingly mutually exclusive subgroups
of this entity.
BRAF genotype may also have prognostic implications. Some
have argued KIAA1549:BRAF may lead to a less-aggressive
phenotype. In a study of 58 subtotally resected PAs, Hawkins
et al. found 5-year progression-free survival to be 65% in fusion
patients and 17% in wild type (p = 0.002) (18). While Horbinski
et al. found BRAF fusion in PAs to be associated with better
prognosis as well, this was not statistically significant (19). It
is speculated that the less-aggressive phenotype in BRAF fusion
patients may result from the phenomenon of oncogene-induced
cell senescence (18).
Overall, survival rates in pediatric pilocytic astrocytoma are
excellent, generally exceeding 90% at 5 years (20, 21).
Diffuse glioma
The diagnosis of diffuse glioma has evolved with the
incorporation of molecular markers, but remains particularly
challenging. The 2016 WHO revised guidelines identified
the importance of IDH1/2 and 1p/19q codeletion status
for classification of diffuse gliomas into astrocytic or
oligodendroglial phenotypes. However, pediatric diffuse gliomas
rarely demonstrate these findings (22). BRAF aberrations, by
contrast, are more frequent in the pediatric population (6, 22).
While studies in adults estimate the prevalence of all BRAF
mutation at less than 1% (7, 23), in children and adolescents
rates are estimated to be 3% for fusion, and 8–43% for V600E.
(6, 15, 24). This might indicate somewhat distinct molecular
underpinnings in evolution of diffuse gliomas in adults when
compared with the pediatric population.
There is a low incidence of diffuse glioma in children, with
less than 10% of pediatric low grade gliomas falling into this
category in some studies (20). In addition, they are frequently
examined in combination with other subtypes of low-grade
glioma in studies. Prognostic predictions in this population are
therefore challenging. However, limited data do suggest that
V600E may be associated with more aggressive phenotype. In
a large series of pediatric low-grade gliomas, Lassaletta et al.
revealed V600E mutations in 10 of 23 diffuse astrocytomas
(43%), 2 of 15 pilomyxoid astrocytomas (13%), and 14 of 70 low
grade gliomas not otherwise specified (20%) (24). They analyzed
outcomes from these patients in combination with other low
grade gliomas and found V600E was associated with worse 5 year
(50.1 vs. 72%) and 10 year PFS (27 vs. 60.2%) (24). The cIMPACT-
NOW update four guidelines suggest using a designation “diffuse
glioma, BRAF V600E-mutant” for tumors exhibiting a BRAF
V600E mutation (25).
In adults, grade II diffuse gliomas account for 24% all CNS
cases and are found largely within the cerebral hemispheres.
BRAF mutations occur in less than 1%, limiting prognostic
assessments. The most important predictors of prognosis in this
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FIGURE 2 | Frequency of BRAF alteration in pilocytic astrocytoma based on location (References: 5, 7, 8, 18, 19, 102). *: all the listed values are approximate
numbers. NF1, Neurofibromatosis 1; PA, pilocytic astrocytoma.
tumor subset remain extent of resection, tumor location, and
patient age (6, 19).
Pleomorphic xanthoastrocytoma
Pleomorphic xanthoastrocytoma (PXA) accounts for less than
1% of all astrocytic tumors, but is more frequent in children
(10, 26). These tumors show a predilection for the temporal lobe
and superficial cortices (10). BRAF V600E is highly enriched in
this population, with 2/3 of adult and pediatric cases bearing it,
including a smaller number of cases with anaplasia (33% of such
cases) (7).
Overall, prognosis for PXA is favorable, with recurrence-free
survival estimated to be 64% following initial resection (27).
The prognostic utility of BRAF V600E has been investigated, but
remains indeterminate (27–29).
In addition to BRAF, PXA frequently features aberrations
in CDKN2A, which encodes for the cyclin dependent kinase
inhibitor p16 (9). In a study of 38 primary and anaplastic PXAs,
87% were found to exhibit a homozygous deletion. However, this
deletion did not correlate with BRAF status, as it was distributed
equally among wild type and mutant tumors (30). In this same
cohort, BRAF status did not clearly confer survival benefit.
High Grade Gliomas
The frequency of BRAF mutations in adult GBM is estimated to
be 1–3% (31). However, certain cohorts have higher frequencies.
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FIGURE 3 | Pilocytic astrocytoma with compact areas harboring piloid cells,
abundant Rosenthal material, and some multinucleate cells (“pennies on a
plate”) (H&E; A) and florescence in situ probe showing KIAA1549:BRAF
fusion. Yellow signal signifies fusion (B).
Glioblastomas in teenage and young adults are enriched for the
V600E mutation, and it may be observed in up to 50% of the
epithelioid variant (31, 32, 33) (Figure 4C).
Glioneuronal Tumors
Ganglioglioma (GG)
Ganglioglioma accounts for 7% of childhood and adolescent
primary CNS tumors (26). These are slow growing,
circumscribed tumors that may harbor both cystic and
solid components (10). Histologically they show neuronal
(comprised by generally ganglionic) and glial elements in
variable proportions (Figure 4A). BRAF missense mutations are
estimated to be found in half of specimens, with BRAF fusions
seen in another 10–25% (6, 7, 34). In a series of 53 pediatric
gangliogliomas, Dahiya et al. found BRAF V600E to be associated
with shorter recurrence free survival (35).
Diffuse Leptomeningeal Glioneuronal Tumor
Diffuse leptomeningeal glioneuronal tumor (DLGNT) is a rare
entity added only recently to the WHO classification of CNS
tumors, and these have not been assigned a WHO grade
as their natural history is not clearly delineated yet (10).
It is characterized by leptomeningeal spread of histologically
monomorphic, oligodendroglial-like cells, usually in children
and adolescents. Molecularly, it features loss of 1p, without an
abnormality in IDH (10, 36, 37). In a review of 30 cases, Deng
et al. demonstrated pathologic activation of the MAPK pathway
in 80%, and suggested this to be a hallmark molecular feature
of this tumor (37). In 66% of their specimens, this was a result
of KIAA1549:BRAF (37). They further defined and characterized
two molecular subclasses using DNA methylation profiling. Class
1 was found more commonly in younger patients (median age 5),
with frequent 1p/19q codeletions (47%), and was associated with
100% 5-year progression free survival. Subclass 2 tended to arise
in older patients (median age 14), who experienced 43% 5 year
overall survival. BRAF fusions were observed equally in the two
groups (76% in class 1 vs. 77% in class 2).
Polymorphous Low Grade Neuroepithelial Tumor of
the Young (PLNTY)
In 2017, Huse et al. described a new entity of low-grade,
oligodendroglioma-like neuroepithelial tumor, naming this
polymorphous low grade neuroepithelial tumor of the young
(PLNTY) (38). These are, generally, epileptogenic tumors located
in the subcortical temporal lobe and associated with dystrophic
calcifications (39, 40). Histologically, these tumors show a
diverse astrocytic and ependymal appearance, though frequently
there is an oligodendroglioma-like component (38). There is
immunoreactivity for CD34 and OLIG2. Tumor cells lack IDH1
R132H or 1p/19q co-deletion. Nearly all, however, featured
overactivation of the MAPK pathway (38). In Huse’s original
series, 3 of 7 cases were BRAF V600E mutant and the remaining
cases exhibited FGFR2/3 fusion events (no BRAF fusion was
detected) (38).
Multinodular and Vacuolating Neuronal Tumor (MVNT)
Multinodular and vacuolating neuronal tumor (MVNT) is a
provisional entity included in the 2016 WHO classification of
CNS tumors (10). Due to their indolent behavior and ease
of surgical excision, Huse et al. suggest assigning this entity
a WHO grade I designation, however, a formal WHO grade
has not yet been assigned (41). MVNT is a supratentorial
tumor which generally appears on MRI as multiple subcortical,
FLAIR-hyperintense nodules (42). Histologically the tumor cells
arrange into clusters and have conspicuous intracytoplasmic
and stromal vacuolation (41, 43). They express OLIG2, CD34,
and are also labeled by anti-HuC/HuD with variable expression
of synaptophysin, and no reactivity for chromogranin, NeuN
and/or neurofilament (10, 41). In their original description
Pekmezci et al., analyzed eight samples using phospho-
ERK immunohistochemistry and demonstrated uniform MAPK
pathway overactivation in this tumor (43). With next-generation
sequencing, they subsequently revealed mutations in BRAF,
MAP2K1, and FGFR2 as candidate drivers (43). Although the
sample size in this study was small, interestingly, the two BRAF
mutations observed were L597R and G469S and not V600E.
Though uncommon, these have previously been described
in langerhans cell histiocytosis, Erdheim-Chester disease, and
melanoma (43).
Non-neuroepithelial Tumors
Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is the most common
histiocytic tumor affecting children. Within the CNS, these
are usually found in the skull or hypothalamus. BRAF point
mutation is found in an estimated 69% of cases, with 47% of
those representing V600E (44). Other mutations include T599A,
600DLAT insertion and BRAF V600D (45).
BRAF alteration portends worse clinical course, as shown by
Heritier et al. where they studied 315 patients, of which 55% were
harboring V600E, and found this was associated with a seven-fold
increased risk of resistance to standard treatment (21.9 vs. 3.3%)
(46). These patients also reactivated at a higher rate over a 5 year
follow-up (42.8 vs. 28.1%), and experienced more permanent and
severe sequelae (46).
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FIGURE 4 | (A) Ganglioghoma (H&E); (B) Papillary craniopharyngioma (H&E); (C) Epithelioid glioblastoma (H&E); (D) BRAF immunostaining showing diffuse positive
staining (BRAF IPX).
Craniopharyngioma
Craniopharyngioma is a benign, WHO grade I tumor that has
relatively low risk of mortality, but causes significant morbidity in
terms of endocrine and visual function (Figure 4B). Interestingly,
though the two subtypes (i.e., adamantinomatous and papillary)
are associated with strongly dichotomous molecular features,
they behave largely similarly in patients, aside from age of initial
presentation. In terms of morbidity and mortality, there are to
our knowledge no studies correlating tumor subtype with long
term outcome. Karavitaki, for example, reviewed 121 cases of
craniopharyngioma and found no difference in overall survival
at 10 years (47).
In 2014 Brastianos et al. revealed the V600E substitution
in 95% of 39 papillary specimens (48). Meanwhile, 96% of
adamantinomatous subtypes were shown to harbor mutations in
CTNNB1 and all adamantinomatous specimens were BRAF wild-
type. The authors therefore proposed these markers defined two
distinct and mutually exclusive clonal patterns (48). Since the
original account, rare adamantinomatous specimens have been
discovered to bear BRAF V600E (49). However, the specificity of
distinct alterations overall remains very high.
Glomus Tumor
Glomus tumors are seldomly encountered mesenchymal
neoplasms, and typically follow a benign clinical course (50,
51). Most glomus tumors are superficial, less than 2 cm, and
surgically curable (52). BRAF V600E appears with a frequency of
6–11% (50, 51, 53). Its presence in glomus tumors may predict
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a more aggressive phenotype (53). Karamzadeh et al. reviewed
102 cases, largely originating from the extremities (53). In this
series BRAF V600E was not observed in any of 57 benign cases,
but was enriched in tumors of uncertain malignant potential
(3/14, 21%) and malignant varieties (3/24, 12%). These tumors
showed atypical histological features including deep location,
size more than 2 cm, infiltrative growth, and mitotic count of
≥5/50 HPFs (53).
MALIGNANT PERIPHERAL NERVE
SHEATH TUMORS
Malignant peripheral nerve sheath tumors (MPNST) comprise 5–
10% of all soft tissue sarcomas, are usually deep seated, and arise
from a peripheral nerve trunk (54). 50% are associated with NF1.
Overall, NF1 patients have an 8–13% lifetime risk of developing
it (55). The rate of BRAF V600E in all MPNSTs is estimated to
be 6.5% (2.9% in NF1, 11.9% sporadic) (56). BRAF fusions have
also been reported, though these are less frequent. (56) Little
is currently known about the prognosis of a BRAF mutation
in MPNSTs (55, 56), though one group found no statistically
significant differences in survival or time to between mutant and
wild-type cohorts (55).
METASTATIC TUMORS TO THE CNS
Brain metastases are the most common intracranial neoplasm
in adults, with an incidence estimated at between 8.3 and 11
per 100,000 (57). The most frequent primary tumors are lung,
melanoma, breast, renal, and colorectal (57). The role of BRAF
is under intense study in several of these contexts. CNS-specific
outcomes, however, are ill-defined.
Estimates of BRAF aberration in non-small-cell lung
carcinoma are less than 10% (58). In one large series of 1,046
cases, rates were 4.9% in adenocarcinoma and 0.3% in squamous
cell carcinoma (58). V600E accounted for 57% of the total
aberrant BRAF in cases of adenocarcinoma and squamous cell
carcinoma in this study, and was independently associated with
poorer prognosis. The study did not examine CNS specific
outcomes, however.
In melanoma, BRAF mutations are found in approximately
50% of stage IV disease, and of those roughly 70% are V600E
and 20% are V600K (59). BRAF mutation is associated with
slightly younger age at primary diagnosis, but does not appear
to influence overall survival (60, 61). Kotecha et al. found that for
patients who had stereotactic radiosurgery, the 12 month local
failure rate was higher amongst patients with BRAF wildtype
metastatic melanoma compared with BRAF mutant cases (22%
compared with 6% (62). Prevalence of BRAF mutation in brain-
specific metastases is similar to prevalence in other metastatic
sites (63).
BRAF mutations are rare in breast and renal carcinoma,
but they do occur in 5–10% of patients with metastatic
colon carcinoma (64). Over 95% of these are V600E (64).
These patients exhibit shorter overall survival as compared to
their wild type counterparts (65). CNS-specific outcomes are
unfortunately lacking.
Approximately 25–83% of papillary thyroid carcinoma harbor
BRAF mutation, where it is associated with a more aggressive
phenotype (66). However, this tumor rarely metastasizes to the
brain and in one meta-analysis, BRAF status was not related to
distant metastasis (66).
SUCCESSES AND CHALLENGES IN
TARGETING BRAF
To date, oncogenic BRAF has been targeted with varying
success scale in humans in melanoma, non-small cell lung
cancer, colorectal carcinoma, and thyroid carcinoma, as well
as gliomas and glioneuronal tumors. By far, the majority of
clinical experience has been gained in metastatic melanoma. This
experience has highlighted several challenges that will inform
treatment of patients with BRAF-associated CNS or PNS disease.
Additionally, if these treatments are to gain clinical relevance,
CNS-specific obstacles must be considered.
The first BRAF inhibitors (BRAFi) described were non-
specific “multikinase” inhibitors. These were developed before
recognition of widespread BRAF mutation, including V600E,
in human cancer. Sorafenib (Bayer/Onyx) is the archetypal
agent of this family. This drug was FDA approved for use
in advanced renal cell carcinoma in 2005, for hepatocellular
carcinoma in 2007, and for metastatic thyroid carcinoma in
2013. In a phase III trial in metastatic melanoma, the addition
of sorafenib to carboplatin/paclitaxel failed to improve overall
survival (67). This was likely a result of poor efficacy against
V600E. Importantly, sorafenib was also the first BRAFi to be
associated with paradoxical MAPK activation in BRAF wild-
type and BRAF fusion cells. This was reported in vitro in 1999
(68), but its clinical significance was recognized only later, with
the observation that patients treated for renal cell carcinoma
developed keratoacanthomas and squamous cell carcinomas (69).
In 2011 this adverse effect was highlighted in a phase II trial
of children with low-grade astrocytoma, during which 9 of 11
patients unexpectedly and rapidly progressed following three
cycles of treatment with the drug (70). This led to a premature
termination of the trial. Subsequent experience has reinforced
opinion that this unexpected result was due to paradoxical ERK
activation (70, 71).
Second generation inhibitors include vemurafenib,
dabrafenib, and encorafenib, all of which are currently FDA
approved for use in metastatic melanoma. Unlike sorafenib,
these were specifically engineered to target V600E-bearing BRAF.
Vemurafenib (PLX4032, Zelboraf, Plexxikon/Genentech) was
developed in 2008 by a structure-guided approach and rapidly
underwent phase I and II trials (72). In 2011 data from a phase
III randomized controlled trial comparing vemurafenib to
dacarbazine in patients with unresectable stage IIIc or IV disease
were reported (73). The vemurafenib cohort experienced 63%
relative risk reduction in death and 74% relative risk reduction in
tumor progression (71). Results of a trial comparing dabrafenib
(GSK2118436, Tafinlar, GlaxoSmithKline) to dacarbazine were
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similarly positive (74). Encorafenib was granted approval in 2018
for use in combination with binimetinib, a MEKi.
Second-generation inhibitors also induce MAPK activation
in non-V600E cells, leading to the adverse effect of secondary
cutaneous neoplasm in 14–26% of patients (75). Similarly to
sorafenib, this includes cells bearing BRAF fusion protein.
In vitro, cortical neurospheres containing KIAA1549-BRAF
treated with an analog of vemurafenib exhibit paradoxical
growth (71).
While second generation inhibitors target V600E, an FDA-
approved therapy specific to KIAA1549:BRAF is lacking. Current
strategy for these tumors is toward targeting other molecules
in the MAPK pathway. In vitro, cells bearing BRAF fusion are
susceptible to MEK inhibitors such as selumetinib, binimetinib,
trametinib, and cobimetinib (76, 77). In vivo, success has also
been achieved in some patients. One phase II trial studied
selumetinib in recurrent or refractory BRAF-aberrant or NF1
associated low-grade gliomas (78). In a subset of 18 patients
harboring the KIAA1549:BRAF fusion, seven (39%) exhibited
partial response (78). Two randomized, controlled trials are
currently comparing selumetinib with standard chemotherapy in
pediatric low-grade glioma (78). In addition, next-generation Raf
inhibitors in phase I/II trials may also have efficacy against BRAF
fusion proteins (79, 80).
Acquired resistance has proved to be the major obstacle to
durable response in patients with a variety of cancers treated
with BRAFi. In melanoma, median response duration to BRAFi
monotherapy is just 5–8 months (81). It is generally accepted that
acquired resistance to BRAFi occurs via reactivation of the MAPK
and, to a lesser extent, PI3K/mTOR pathways. This can result, for
example, from overexpression or mutation in Ras that bypasses
Raf, or by secondary activating mutations in MEK (82, 83).
Combination BRAFi + MEKi has improved clinical responses,
likely by addressing this escape mechanism. In melanoma,
BRAFi + MEKi extends duration of response to 9.5 months
(81). Consequently, combination therapy is now standard-of-
care. Resistance to combination therapy is being investigated, but
appears to involve similar mechanisms of upstream activation
and parallel activation of the PI3K/mTOR pathway.
One CNS-specific obstacle to BRAF targeted therapy may be
the blood-brain or blood-tumor barrier. There is some suggestion
of this effect in data from trials in metastatic melanoma. The
phase II COMBI-MB trial evaluated the efficacy of dabrafenib
plus trametinib in patients with BRAF V600E positive melanoma
with asymptomatic brain metastases (84). Whereas median
response duration was 10.2 months for extracranial disease, it
was just 6.5 month for intracranial disease (84). Some preclinical
data do suggest that brain bioavailability of BRAFi may be
limited by this barrier. In vitro, Durmus et al. found vemurafenib
was efficiently effluxed by transporters of the ATP-binding
cassette family (ABC), which are active in the blood-brain
barrier (85). In vivo, those mice coadministered vemurafenib with
elacridar, an inhibitor of ABCG2, experienced increased brain
concentrations of drug (85).
In glioma, clinical trial data of BRAFi are thus far limited. VE-
BASKET was a non-randomized, open-label study that evaluated
vemurafenib monotherapy in patients with WHO grades I-IV
glioma harboring the V600E mutation (86). It enrolled 24
subjects: 7 PXA, 2 PA, and 15 grade III/IV gliomas. 20% of
these patients had partial response, 40% had stable disease
and one complete response was observed in a PXA. Overall,
responses in lower-grade tumors were better, though sample
sizes were small and this difference did not reach statistical
significance (86). Hargrave et al. more recently reported the
results of dabrafenib monotherapy in a subset of pediatric
patients with recurrent, BRAF mutant, low grade glioma (87).
Of their 32 patients, 44% experienced objective response by
response assessment in neuro-oncology (RANO) criteria, as
compared to the apparent rate of 10% in historical controls
treated with standard of care. Mean duration of response was
11 months. Other case series and reports have confirmed similar
findings (31, 88–90).
There is reason to believe BRAFi + MEKi may be superior
to BRAFi monotherapy in glioma as in other cancers. In
an animal model of V600E high-grade glioma, Grossaeur
et al. documented longer treatment effects when analyzing the
frequency of proliferative tumor cells with combination therapy
(91). They also suggested combined BRAFi + MEKi therapy may
prevent secondary RAS driven cancers, such as squamous cell
carcinomas, which can be seen with monotherapy (91). Small
series of combination in both pediatric and adult high grade
glioma have also demonstrated occasional rapid and durable
responses (31, 92). A phase II trial (NCT02684058) is currently
underway studying dabrafenib and trametinib in children and
adolescent patients with BRAF V600E low grade glioma and
adults with relapsed or refractory high grade glioma (92).
Papillary subtype craniopharyngioma is another obvious
target for investigation given its high (95%) prevalence of
V600E. Several groups have described cases of dramatic and
sometimes-sustained response to BRAFi with or without MEKi
(93–98). A multi-institutional phase II trial (Alliance A071601) is
currently underway to test the combination of vemurafenib and
cobimetinib) (98).
BRAF TESTING IN NEUROPATHOLOGY
In testing for BRAF aberration, knowledge of the broader clinical
context, as well as the limitations of tissue and available tests, will
help to optimize testing algorithms.
Molecular platforms are the “gold standard” of BRAF analysis.
These include Sanger Sequencing, allele specific polymerase chain
reaction (PCR), pyrosequencing, High Resolution Melting curve
and Next Generation Sequencing (NGS) (99, 100). High fidelity
sequencing is the most sensitive test for a wide variety of possible
aberrations. However, the ability to perform these tests may be
limited by the quality and quantity of tissue and the ability
to extract high-quality DNA. These tests may also be cost-
prohibitive.
Such circumstances thus call for immunohistochemistry as a
triage before performing the molecular testing. It has been shown
that the most frequent and clinically relevant point mutation
is V600E, against which a commercially available monoclonal
antibody currently exists (Figure 4D). Easy to perform and
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relatively inexpensive, this stain may be used either as a screen to
be followed by more dedicated testing, or alternately in isolation.
The sensitivity of this test has been shown to be near, or at, 100%
(101). However, false negatives may still result from freezing or
surgical cautery artifact, prompting some caution (2).
Fluorescence in situ hybridization fusion and break apart
probes for KIAA1549-BRAF provide a reliable method for
diagnosis of fusion genes (Figure 3B). Because of the
heterogeneity of observed KIAA1549-BRAF fusions, the tester
must be attuned to whether the probe is a fusion or break apart
probe, and in the case of a break apart probe, the specific exon
(Table 1).
Even with detailed molecular analysis available, the limitations
to apply this knowledge must be recognized as our experience
is still evolving. An example from the pediatric context is
instructive. Given a limited sample of a pediatric brain tumor
featuring piloid glial cells with or without Rosenthal fibers,
and eosinophilic granular bodies, the presence of a BRAF
fusion may be highly suggestive, but not pathognomonic, of
a pilocytic astrocytoma (36, 102). Molecular findings always
require correlation with the patient’s clinical, histological, and
radiologic details.
CONCLUSION
BRAF alterations are identifiable using current diagnostic
techniques, and at present play an important role in the
pathologic workup of CNS tumors and to a lesser degree in
PNS. BRAF targeted therapies, particularly newer generation
and in combination, hold promise for use against several
subtypes of tumors.
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